Well stock may be trailing off due to this recent statement by Ceo
So maybe longer to trial completion and data then what they previously projected
Kiwi
Our previous estimates assumed a ramp in the enrollment rate at this stage of the trial, but we have seen more of a steady enrollment rate in the last few weeks.
So maybe longer to trial completion and data then what they previously projected
Kiwi
Recent AMLX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/26/2026 08:00:07 PM
- Amylyx Pharmaceuticals Announces Peer-Reviewed Publication of Phase 2 Open-Label HELIOS Trial Data for AMX0035 in The Journal of Clinical Investigation • Business Wire • 05/15/2026 04:11:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 11:04:48 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 11:02:56 AM
- Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results • Business Wire • 05/07/2026 11:00:00 AM
- Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences • Business Wire • 05/06/2026 01:00:00 PM
- Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia • Business Wire • 05/05/2026 11:00:00 AM
- Amylyx Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026 • Business Wire • 04/30/2026 01:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/23/2026 11:03:13 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/23/2026 11:02:00 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/23/2026 11:01:02 AM
- Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference • Business Wire • 04/08/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 11:11:11 AM
- Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia • Business Wire • 03/24/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2026 08:00:08 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2026 08:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 09:00:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2026 09:00:02 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/03/2026 09:03:34 PM
- Amylyx Shares Slip Despite Q4 Beat as Investors Focus on Trial Timeline • IH Market News • 03/03/2026 03:54:22 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 03/03/2026 01:01:18 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/03/2026 12:10:58 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 12:02:50 PM
- Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results • Business Wire • 03/03/2026 12:00:00 PM
